WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • Healthcare and FDA Regulatory
  • National Security and Trade
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • FDA Regulatory and Compliance

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Insights
Type
People
Practices
Industries
From Date
To Date
Reset Search

Search Results

Client Highlights

11.16.26

Wilson Sonsini Advises Fractile on $720 Million Series C
On November 11, 2026, Fractile, a chip-first frontier AI company, announced the completion of a $720 million Series C financing led by Thrive Capital, Founders Fund, Lightspeed, and Redpoint. CapitalG, DST Global, Elad Gil, BlackRock, Bain Capital Ventures (BCV), T. Rowe Price, SV Angel, Sovereign AI, British Business Bank, Shopify Ventures, Felicis, Gigascale Capital, 20VC, Georgian, and Balderton, as well as other existing investors,​ also participated in the round. Wilson Sonsini Goodrich & Rosati advised Fractile on the transaction.
Client Highlights

11.16.26

Wilson Sonsini Advises Frontage Holdings on Privatization and Asset Restructuring
On November 9, 2026, Frontage Holdings Corporation (Frontage) announced that it has entered into an agreement for (i) a privatization by way of scheme of arrangement through SanRex Limited, the offeror held by an investor consortium, and (ii) a subsequent asset restructuring (together, “the transaction”). Wilson Sonsini Goodrich & Rosati advised Frontage on the transaction.

Upon completion of the privatization, Frontage will become a wholly owned subsidiary of SanRex Limited. As part of the asset restructuring, Frontage’s business is expected to be divided among members of an investor consortium comprising Charles River Laboratories International, Inc. (expected to own and operate Frontage’s Exton, Pennsylvania-based bioanalysis and drug metabolism and pharmacokinetics (DMPK) business); a wholly owned subsidiary of Hangzhou Tigermed Consulting Co., Ltd., Frontage's controlling shareholder (expected to own and operate Frontage’s PRC-based business and the business currently owned and operated by Acme Bioscience, Inc. and/or its subsidiaries); and Dr. Song Li, chairman of Frontage's board of directors (expected to own and operate Frontage’s remaining business outside of the PRC). The transaction remains subject to shareholder and regulatory approvals.

Frontage is engaged in the provision of research, analytical, and development services throughout the product discovery and development continuum. Frontage provides integrated, scientifically driven support that enables biopharmaceutical and life science companies to achieve their product development goals.

The Wilson Sonsini team that advised Frontage on the transaction includes Yang Chu, Jie Zhu, Nicole Yuen, Yang Liao, Shuhan Zhang, Yuan Dong, and Yingqi Gu.

For more information, please refer to Frontage’s press release and the HKEX announcement.
Client Highlights

11.16.26

Wilson Sonsini Advises Galvanize Therapeutics on Oversubscribed $130 Million Series D
On November 16, 2026, Galvanize Therapeutics®, a commercial-stage company pioneering pulsed electric field (PEF) ablation technologies for oncology and chronic disease, announced the closing of an oversubscribed $130 million Series D financing. Wilson Sonsini Goodrich & Rosati advised Galvanize Therapeutics® on the transaction.
Client Highlights

11.13.26

Wilson Sonsini Advises Crosspoint Capital on Kindo's $30 Million Financing
On November 12, 2026, Kindo, an AI agent management platform, announced a $30 million raise co-led by Crosspoint Capital and Forgepoint Capital, bringing total funding to $57.6 million. TFX Capital and CircleRock Capital joined, alongside existing investors. Wilson Sonsini Goodrich & Rosati advised Crosspoint Capital on the transaction.
Client Highlights

11.13.26

Wilson Sonsini Advises Delix Therapeutics on IP Matters Related to $100 Million Series C Financing
On November 9, 2026, Delix Therapeutics (Delix), a clinical-stage neuroscience company pioneering the discovery and development of neuroplastogens, announced the closing of an oversubscribed $100 million Series C financing. The round was led by Johnson & Johnson Innovation – JJDC, Inc., the corporate venture capital organization of Johnson & Johnson, and SV Health Investors’ Dementia Discovery Fund, with participation from existing investors including RA Capital, UC Investments, Artis Ventures, OMX Ventures, Dolby Family Ventures, and Bail Capital, as well as new investors, including Adage Capital Management, Hamilton Square Partners Management, Vestal Point Capital, and YK Bioventures, among others. Wilson Sonsini Goodrich & Rosati advised Delix on the intellectual property matters related to the transaction.
Client Highlights

11.11.26

Wilson Sonsini Advises PacBio on $100 Million At-the-Market Stock Offering
On November 10, 2026, Pacific Biosciences of California, Inc. (PacBio), developer of the world’s most advanced sequencing technologies, entered into a sales agreement with Allen & Company LLC to offer up to $100 million of its common stock through an at-the-market program. Under the terms of the agreement, PacBio may offer and sell shares of its common stock having an aggregate offering price of up to $100 million from time to time through or to Allen & Company LLC, acting as PacBio’s sales agent or principal. Wilson Sonsini Goodrich & Rosati advised PacBio on the transaction.

PacBio intends to use the proceeds from this offering, together with existing cash, cash equivalents, and investments, for research and development and working capital and general corporate purposes.

The Wilson Sonsini team that advised PacBio on the transaction included Andrew Hoffman, Zachary Myers, Annie Giomi, James Keegan, and Mounika Yepuri.

For more information, please see PacBio’s prospectus supplement.
Client Highlights

11.10.26

Firm Represents Veteran Ventures Capital as Lead Investor in $6.95 Million Aformic Financing
On November 4, 2026, Veteran Ventures Capital (VVC) announced that it led a $6.95 million investment in Aformic, a robotics company that designs and deploys autonomous mobile robots and fleet-management software. Wilson Sonsini Goodrich & Rosati advised VVC on the transaction.
Client Highlights

11.10.26

Wilson Sonsini Advises Ancep on $8.5 Million Funding Round
On November 10, 2026, Ancep, a London-based start-up building artificial intelligence (AI) agents for commercial insurance brokers, emerged from stealth and announced it raised $8.5 million in a funding round led by Creandum. The round also included participation from Kleiner Perkins and Vicus Ventures, alongside angel investors including Christa Davies, former chief financial officer of Aon, and operators from OpenAI, Anthropic, and Google DeepMind. Ancep will use the new funds to support growth and hiring. Wilson Sonsini Goodrich & Rosati advised Ancep on the transaction.
Client Highlights

11.10.26

Wilson Sonsini Advises Graphon Labs on $35 Million Series A
On November 10, 2026, Graphon Labs, an applied artificial intelligence (AI) lab building Persistent Intelligence to power the next generation of AI agents and accelerate progress toward artificial general intelligence, announced a $35 million Series A led by RRE Ventures, with participation from HP, Energy Impact Partners, Hitachi Ventures, and Gaia VC. Wilson Sonsini Goodrich & Rosati advised Graphon Labs on the transaction.
Client Highlights

11.09.26

Wilson Sonsini Advises HZO on Acquisition by Forge Nano
On November 5, 2026, Forge Nano Holdings, Inc. (Forge Nano), a semiconductor equipment and advanced materials company whose Atomic Layer Deposition (ALD) technology serves AI-era chip manufacturing and defense battery applications, announced that it has completed the acquisition of HZO, Inc., a leading provider of protective nanocoatings for electronics. The combination pairs Forge Nano’s ALD platform with HZO’s high-volume Parylene and thin-film protective coating business and its blue-chip customer base in the consumer electronics, energy, IoT, medical, and automotive industries. Wilson Sonsini Goodrich & Rosati advised HZO on the transaction.
Client Highlights

11.09.26

Wilson Sonsini Advises KymaThera on IP Matters Related to $80 Million Series B
On October 6, 2026, KymaThera, a biotechnology company developing next-generation precision medicines for genetically defined diseases, announced the closing of an $80 million Series B financing led by Alta Partners, with participation from Venrock, Foresite Capital, J. Wood Capital, and others. Wilson Sonsini Goodrich & Rosati advised KymaThera on intellectual property matters related to the financing.
Client Highlights

11.09.26

Wilson Sonsini Advises Skydio on $1.2 Billion Axon Investment
On November 5, 2026, Axon, a global leader in public safety technology, announced an additional $1.2 billion investment in Skydio, the largest U.S.-based drone manufacturer and a world leader in flying robots. The agreement, which will add approximately 20 percent to Axon's fully diluted ownership in Skydio at a $5.2 billion pre-money valuation, builds on a partnership that is already bringing Skydio drones to public safety agencies across the U.S., marking a major expansion of Axon's Drone as First Responder (DFR) program. Axon will also become Skydio's exclusive distributor for public safety in the U.S. and Canada. Wilson Sonsini Goodrich & Rosati advised Skydio on the transaction.
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Cookie Settings
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.